Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3” by M. P. Goetz et al.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3” by M. P. Goetz et al.

Published:2024-08 Issue:8 Volume:35 Page:747-748
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sherry A.D.^ORCID,Lin T.A.^ORCID,McCaw Z.R.^ORCID,Ludmir E.B.

Funder

National Cancer Institute

University of Texas MD Anderson Cancer Center

Andrew Sabin Family Foundation

Publisher

Elsevier BV

Reference5 articles.

1. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3;Goetz;Ann Oncol,2024

2. Pitfall in the design and analysis of comparative oncology trials with a time-to-event endpoint and recommendations;McCaw;JNCI Cancer Spectr,2022

3. Assessment of median and mean survival time in cancer clinical trials;Das;JAMA Netw Open,2023

4. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer;Goetz;J Clin Oncol,2017

5. Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications;Rahman;Clin Cancer Res,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP